Elanix has exclusive commercialization rights to products invented by the company founder and owned by the University of Lausanne (CHUV) from which Elanix spun-off in 2013.

More patents and IP related to progenitor cell handling and deployment are under preparation.

Core progenitor cell preparation know-how and CFPC®(Cell Free Protein Complex) active ingredient composition will be kept as a company secret.